Between @ and @ , @ men with locally advanced prostate cancer were randomly allocated , using a @ @ trial design , to @ months i.m. leuprorelin ( androgen suppression -LSB- AS -RSB- ) before radiotherapy alone @ months additional leuprorelin @ months zoledronic acid ( ZdA ) , commencing at randomization .